Carbon Health founder steps back from top role, Kaiser hospitals roll out AI scribe
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
Category: Pharma
STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Is pharma still fearful of the Inflation Reduction Act?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: What do Biden’s drug price comparisons reveal? Not much
WASHINGTON — The White House is touting just how much its new Medicare negotiation process…
.jpg)
Antiviral used for mpox no better than placebo, NIH says
The National Institutes of Health said Thursday that an antiviral often used to treat mpox…
.jpg)
We have mpox vaccines now. But how will they be distributed?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more
Top of the morning to you, and a fine one it is. The skies are…
Medicare drug price negotiation didn’t benefit Biden — but it may help Harris
WASHINGTON — When Vice President Kamala Harris takes the stage at the Democratic National Convention…
STAT+: Medicare announces drug prices for historic first round of negotiations
WASHINGTON — The day drug makers dreaded has finally arrived. Medicare officials on Thursday unveiled…
Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs
As many as 40,000 chronically ill seniors are choosing to endure uncomfortable, time-consuming intravenous infusions…
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
STAT+: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Syros shares battered after it stops leukemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more
Rise and shine, everyone, another busy day is on the way. Our mascots, for instance,…
Atai advances oral psychedelic in depression
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
A tough week for MDMA-assisted psychotherapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
DO NOT PUBLISH: FDA rejects MDMA as a psychedelic treatment for PTSD
The Food and Drug Administration rejected MDMA as a treatment for post-traumatic stress disorder on…
FDA approves EpiPen alternative, a nasal spray for anaphylaxis
On Friday, the Food and Drug Administration approved the first needle-free treatment for adults and…
Why did Novo pull heart failure paperwork for Wegovy?
Hey, humans. Today, we talk about the decades-long pursuit to get MDMA approved as a…
STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Judge rules against Chamber of Commerce in Medicare drug negotiation lawsuit
WASHINGTON — A federal judge on Thursday tossed out a U.S. Chamber of Commerce lawsuit…
STAT+: A strong start for Madrigal’s MASH drug launch
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more
Top of the morning to you, and a fine one it is, despite the gray…
Sarepta CEO: We’re ‘pretty brilliant’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Watch: How drug patents pave the way to profit
This is Part 3 of “Behind the Counter,” an in-depth video series demystifying the complex…
STAT+: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
A new drug for glioma means a windfall for Agios
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming…
The exclusive biotech stories you need to read
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers
Roche, the Swiss pharmaceutical giant, earlier this year abruptly cancelled an international clinical trial of…
STAT+: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
FDA ad comm favors Zevra’s Niemann-Pick drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Weight loss drugs without a prescription? Study warns it’s a “very risky business”
In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s,…
STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more
Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences…
Moderna is still in a Covid hangover
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
venBio raises $528 million for its fifth fund
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed for the…
The debate over how long to use Alzheimer’s drugs
Good morning. We have a new investigation out today about how Mount Sinai in New…
STAT+: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more
Good morning, folks! The Dean of Pharmalittle University, Ed Silverman, is out on vacation. I…
Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: How to tell if Biden drove a hard bargain on drug prices
WASHINGTON — The deadline for announcing how much Medicare lowered drug prices in the first…
The biotech news you need from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a critical video, Roche fast-tracking an obesity pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more
And so, another working week will soon draw to a close. Not a moment too…
The worst for Dexcom may not be over
Want to stay on top of the science and politics driving biotech today? Sign up to get…